Article

MVRF awards $1.2 million to retinal research grantees

The Macula Vision Research Foundation (MVRF) has announced its 2013-2014 grant recipients.

West Conshohocken, PA-The Macula Vision Research Foundation (MVRF) has announced its 2013-2014 grant recipients.

The national nonprofit organization, focused on funding research to find a cure for age-related macular degeneration and other retinal diseases, will provide the grantees $100,000 a year for 3 years to fund their basic research projects that are directly aligned with the mission of MVRF to find treatments and a cure for degenerative eye diseases.

"Some of the scientists we have funded have identified the gene for Leber congenital amaurosis, a disease which causes blindness in children," said Karen and Herb Lotman, founders of MVRF. "We are eager for our new grantees to follow the same path with their research and continue to carry out our mission to find a cure for these types of diseases."

The four grantees receiving funding are:

  • Frans Cremers, PhD, a professor at Radboud University’s Nijmegen Medical Center, Netherlands, who will be using state-of-the-art technology to identify gene variants in seven different retinal degenerative diseases that have no known associated gene variants.

  • Roxana Radu, MD, a researcher at the Jules Stein Eye Institute, UCLA, who will be researching the possibility of slowing retinal dysfunction, which often leads to macular degeneration, by expressing a specific type of protein in the eye.

  • E. Strettoi, PhD, a senior investigator at the Italian National Research Council's Institute of Neuroscience, Pisa, Italy, who is conducting research on the sphingolipid pathway in the eye to identify the effects it has on retinal degeneration.

  • Sally Temple, PhD, the scientific director and co-founder of the Regenerative Research Foundation’s Neural Stem Cell Institute, Rensselaer, NY, who will attempt to use human stem cells to generate fully functional human photoreceptors.

To date, MVRF has awarded $18.6 million in grants to fund visionary research and is committed to funding the best and brightest researchers in the world.

For more articles in this issue of Ophthalmology Times eReport, click here.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.